Big Rallies Brewing? 3 Analyst Favorites to Watch Closely

Despite mixed Q2 earnings, SkyWater Technology (SKYT), Emergent BioSolutions (EBS), and Backblaze (BLZE) have experienced significant stock rallies (30-48% in the last month), driven by strategic developments and strong analyst optimism. SkyWater's acquisition of Fab 25, projected to generate $300 million in annual revenue and position it for U.S. onshore manufacturing, overshadowed a 37% YOY revenue decline. Emergent BioSolutions' positive EPS, fueled by strong NARCAN sales and cost optimization, alongside international expansion and a $50 million share repurchase, offset a revenue miss. Backblaze reported 16% YOY revenue growth, boosted by AI-driven demand, despite wider GAAP losses, with improving EBITDA margins. All three companies maintain strong analyst buy ratings, signaling potential for continued upside.

Analysis

Despite presenting mixed or lackluster Q2 2025 financial results, SkyWater Technology (SKYT), Emergent BioSolutions (EBS), and Backblaze (BLZE) have all experienced significant stock price appreciation, ranging from 21% to over 48% in the last month. This suggests investors are prioritizing forward-looking strategic developments over recent historical performance. For SkyWater, the market has overlooked a 37% year-over-year revenue drop and widening losses, focusing instead on the transformative acquisition of Fab 25, which is projected to add at least $300 million in annual revenue and strategically position the firm to capitalize on U.S. onshore semiconductor manufacturing trends. Similarly, Emergent BioSolutions' revenue miss was overshadowed by a substantial EPS beat, driven by strong NARCAN sales and successful cost optimization that enabled a $50 million share repurchase program and improvements in liquidity. The company's growth outlook is further supported by expanding international contracts, such as a new $65 million deal. Backblaze exemplifies a growth-focused narrative, where a 16% YOY revenue increase and a 29% surge in storage revenue, fueled by AI-related demand, have outweighed wider-than-expected GAAP losses and negative free cash flow. Across all three companies, unanimous buy ratings from analysts underscore a prevailing bullish sentiment based on these future growth catalysts.

Key Decisions for Investors

• Investors should evaluate these companies based on their forward-looking catalysts, such as SKYT's Fab 25 integration, EBS's continued cost discipline and international expansion, and BLZE's ability to capitalize on AI-driven demand, rather than solely on their mixed trailing earnings.
• Given the substantial recent stock price increases, it is crucial to assess execution risk, particularly monitoring SKYT's ability to realize projected revenue from its new facility and BLZE's path to positive free cash flow and profitability.
• While unanimous analyst buy ratings signal strong confidence, potential investors should consider whether the significant upside from recent catalysts is already reflected in the stocks' elevated prices before initiating new positions.